Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II ramucirumab + paclitaxel as second-line treatment in metastatic gastric or gastroesophageal junction adenocarcinoma
KCT0003440Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2016
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ramucirumab, paclitaxel in gastric adenocarcinoma, Esophago-Gastric Adenocarcinoma, gastric cancer (GC), sponsored by Eli Lilly and Company. Started May 2016; status: active, not recruiting.
02
Drugs
ramucirumabpaclitaxel
03
Conditions
gastric adenocarcinomaEsophago-Gastric Adenocarcinomagastric cancer (GC)
Beyond the preview
Go deeper on KCT0003440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003440.